The Circulating Fatty Acid Transporter Soluble CD36 Is Not Associated with Carotid Atherosclerosis in Subjects with Type 1 and Type 2 Diabetes Mellitus
Castelblanco, Esmeralda (Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)
Sanjurjo, Lucía (Institut Germans Trias i Pujol)
Barranco-Altirriba, Maria (Institut d'Investigació Biomèdica Sant Pau)
Falguera, Mireia (Institut Català de la Salut)
Hernández, Marta (Institut de Recerca Biomèdica de Lleida)
Soldevila i Madorell, Berta (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Sarrias, Maria-Rosa (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Franch-Nadal, Josep (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Arroyo, Juan Antonio (Universitat Autònoma de Barcelona. Departament de Medicina)
Fernandez-Real, José-Manuel (Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición)
Alonso Pedrol, Núria (Universitat Autònoma de Barcelona. Departament de Medicina)
Mauricio Puente, Dídac (Universitat Autònoma de Barcelona. Departament de Medicina)

Date:	2020
Abstract:	This study aimed to determine the association of fatty acid transporter plasma soluble cluster of differentiation 36 (sCD36) with subclinical carotid atherosclerosis (SCA). A cross-sectional study was conducted in 1023 subjects, 225 with type 1 diabetes (T1D), 276 with type 2 diabetes (T2D) and 522 who were nondiabetic. Carotid atherosclerotic plaque (CAP) presence was determined using B-mode carotid ultrasound imaging. sCD36 were analysed by ELISA, and CD36 surface receptor and mRNA expression were measured by flow cytometry and real-time PCR. Logistic regression models were used to evaluate sCD36 as a biomarker of SCA. Up to 376 (36. 75%) participants had at least one CAP, 76 T1D, 164 T2D and 136 without diabetes, while the remaining 647 (63. 25%) did not have any CAP. There were no differences in sCD36 between patients with and without CAP in T1D (p = 0. 287) or T2D (p = 0. 513). Although nondiabetic subjects with plaques had lower sCD36 levels than those without (p = 0. 023), the multivariate models revealed no association of sCD36 with CAP in any of the three study groups. No differences were found in surface CD36 or CD36 mRNA expression between the patients with and without CAP. sCD36 is not associated with SCA in type 1 or type 2 diabetic or in nondiabetic subjects.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Atherosclerotic plaque ; Carotid atherosclerosis ; Scd36 ; Type 1 diabetes mellitus ; Type 2 diabetes mellitus
Published in:	Journal of clinical medicine, Vol. 9 (june 2020) , ISSN 2077-0383

DOI: 10.3390/jcm9061700
PMID: 32498389

12 p, 772.7 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles